Lista de obras -

Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells

artículo científico publicado en 2007

Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages

artículo científico publicado en 2012

C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway

artículo científico publicado en 2013

Circulating TRAIL shows a significant post-partum decline associated to stressful conditions

artículo científico publicado en 2011

Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)

scientific article published on 01 February 2010

GM-CSF exhibits anti-inflammatory activity on endothelial cells derived from chronic venous disease patients

artículo científico publicado en 2013

Human colostrum and breast milk contain high levels of TNF-related apoptosis-inducing ligand (TRAIL).

artículo científico publicado en 2012

Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells

artículo científico publicado en 2011

Inhibitory effect of natural anti-inflammatory compounds on cytokines released by chronic venous disease patient-derived endothelial cells

artículo científico publicado en 2013

Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation

artículo científico publicado en 2006

Levels of TNF-related apoptosis-inducing ligand (TRAIL) show a long-term stability in the breast milk of mothers of preterm infants

artículo científico publicado en 2013

MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway

artículo científico publicado en 2007

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

artículo científico publicado en 2009

Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.

artículo científico publicado en 2010

Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin

artículo científico publicado en 2008

Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1.

artículo científico publicado en 2012

Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice

scientific article published on 25 September 2006

TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.

artículo científico publicado en 2004

TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors

artículo científico publicado en 2008

Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells

artículo científico publicado en 2011

Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells

artículo científico publicado en 2003

Lista de obras de

Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells

Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages

C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway

Circulating TRAIL shows a significant post-partum decline associated to stressful conditions

Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)

GM-CSF exhibits anti-inflammatory activity on endothelial cells derived from chronic venous disease patients

Human colostrum and breast milk contain high levels of TNF-related apoptosis-inducing ligand (TRAIL).

Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells

Inhibitory effect of natural anti-inflammatory compounds on cytokines released by chronic venous disease patient-derived endothelial cells

Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation

Levels of TNF-related apoptosis-inducing ligand (TRAIL) show a long-term stability in the breast milk of mothers of preterm infants

MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.

Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin

Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1.

Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice

TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.

TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors

Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells

Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells